Assertio Holdings (ASRT) Stock Overview
A pharmaceutical company, provides various products to patients in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for ASRT from our risk checks.
ASRT Community Fair Values
Create NarrativeSee what 30 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Assertio Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.47 |
| 52 Week High | US$20.45 |
| 52 Week Low | US$8.61 |
| Beta | 0.43 |
| 1 Month Change | -3.85% |
| 3 Month Change | 50.90% |
| 1 Year Change | 89.52% |
| 3 Year Change | -79.98% |
| 5 Year Change | -45.99% |
| Change since IPO | -92.30% |
Recent News & Updates
ASRT: Takeover Agreement Will Support Earnings Power And Rerating Potential
Analysts have adjusted Assertio Holdings' price target from about $37.44 to roughly $21.33, reflecting updated views on softer revenue growth, slightly lower profit margins, and a reduced future P/E assumption following recent downgrades related to its takeover agreement. Analyst Commentary Recent research around Assertio Holdings has centered on its takeover agreement and what that means for execution risk, profit quality, and where the shares should trade relative to prior expectations.
ASRT: Reverse Split And 2026 Guidance Will Shape Future Upside Potential
Analysts have kept Assertio Holdings' fair value estimate steady at $28.00, while modestly refining their assumptions around revenue growth, profit margins, and future P/E. This has led to a recalibrated price target that they see as better aligned with updated fundamentals.Recent updates
ASRT: Takeover Agreement Will Support Earnings Power And Rerating Potential
Analysts have adjusted Assertio Holdings' price target from about $37.44 to roughly $21.33, reflecting updated views on softer revenue growth, slightly lower profit margins, and a reduced future P/E assumption following recent downgrades related to its takeover agreement. Analyst Commentary Recent research around Assertio Holdings has centered on its takeover agreement and what that means for execution risk, profit quality, and where the shares should trade relative to prior expectations.ASRT: Reverse Split And 2026 Guidance Will Shape Future Upside Potential
Analysts have kept Assertio Holdings' fair value estimate steady at $28.00, while modestly refining their assumptions around revenue growth, profit margins, and future P/E. This has led to a recalibrated price target that they see as better aligned with updated fundamentals.ASRT: Reverse Split And 2026 Guidance Will Reshape Risk Reward Profile
Analysts have raised their price target on Assertio Holdings from $1.75 to $28.00, citing updated assumptions for revenue growth, profit margins, discount rate, and a lower future P/E multiple in their models. Analyst Commentary Even with a sharply higher price target in some models, not all research views point in the same direction for Assertio Holdings.ASRT: Reverse Split And Earnings Power Will Support Rerating Potential
Analysts have raised their price target on Assertio Holdings, maintaining the figure at $37.44, while citing updated views on fair value, discount rate, revenue growth, profit margin and future P/E as the reasons for the revised assessment. Analyst Commentary Bullish Takeaways Bullish analysts view the reaffirmed $37.44 price target as consistent with their updated fair value work, suggesting the current share price still leaves room for upside if execution tracks their assumptions.
ASRT: Cost Discipline And 15% Margins Will Support Future Upside Potential
Analysts have revised their price target for Assertio Holdings to $45.00. The update reflects slightly adjusted assumptions around discount rate, revenue growth, profit margin and future P/E expectations.Assertio Holdings, Inc.'s (NASDAQ:ASRT) Shares Bounce 35% But Its Business Still Trails The Industry
Feb 07
ASRT: Reverse Split And Earnings Visibility Will Reframe Risk Reward Profile
Analysts have modestly adjusted their price target for Assertio Holdings, citing updated views on discount rates, long term revenue trends and sustainable profit margins, along with a slightly higher assumed future P/E multiple. Analyst Commentary Recent Street research on a comparable operator in the transport and infrastructure space, Asur, offers a useful reference point for how analysts are currently weighing valuation against execution risk when traffic and revenue visibility are in focus.ASRT: Cost Discipline And 15% Margins Will Support Future Upside Potential
Analysts have trimmed their price target on Assertio Holdings to $45.00 from $44.99, reflecting updated assumptions that indicate a smaller revenue decline, higher profit margins near 15%, and a lower future P/E closer to 16x. Analyst Commentary Bullish analysts in the wider market are pointing to companies that maintain or improve profitability targets and trade on mid-teens P/E multiples as potential opportunities for re-rating when execution holds up.ASRT: Reverse Split And New Leadership Will Reframe Risk Reward Profile
Analysts lifted their fair value estimate for Assertio Holdings from $2.69 to $37.44, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E as the key drivers of the new price target range. Analyst Commentary Recent Street research on airport operators with similar business profiles offers some context for how analysts might be thinking about Assertio Holdings, particularly around traffic trends, valuation ranges, and the balance between upside potential and execution risk.ASRT Will Rely On Cost Discipline To Support Future Upside Potential
Analysts have raised their price target on Assertio Holdings significantly, from approximately $3.00 to about $45.00. This reflects a higher assumed fair value multiple despite more conservative expectations for revenue growth and profit margins.Assertio Holdings, Inc.'s (NASDAQ:ASRT) Shares Lagging The Industry But So Is The Business
Dec 24Is Assertio Holdings (NASDAQ:ASRT) Using Debt In A Risky Way?
Sep 18Assertio Holdings, Inc. (NASDAQ:ASRT) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates
May 15Is Assertio Holdings (NASDAQ:ASRT) Using Too Much Debt?
Apr 30
Rolvedon And Sympazan Will Create New Market Opportunities
Strategic market penetration and increased commercial efforts for Rolvedon and Sympazan aim to boost revenue growth.Assertio Holdings, Inc.'s (NASDAQ:ASRT) Revenues Are Not Doing Enough For Some Investors
Mar 14Is Assertio Holdings (NASDAQ:ASRT) A Risky Investment?
Dec 24Little Excitement Around Assertio Holdings, Inc.'s (NASDAQ:ASRT) Revenues As Shares Take 25% Pounding
Nov 15Is Assertio Holdings (NASDAQ:ASRT) Using Debt Sensibly?
Sep 25Assertio Holdings, Inc. (NASDAQ:ASRT) Not Doing Enough For Some Investors As Its Shares Slump 30%
Aug 19There's No Escaping Assertio Holdings, Inc.'s (NASDAQ:ASRT) Muted Revenues Despite A 36% Share Price Rise
Jul 04Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry
May 07Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?
Apr 18Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified
Mar 13Shareholder Returns
| ASRT | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 2.4% | 3.4% | 0.8% |
| 1Y | 89.5% | 27.1% | 27.8% |
Return vs Industry: ASRT exceeded the US Pharmaceuticals industry which returned 27.1% over the past year.
Return vs Market: ASRT exceeded the US Market which returned 27.8% over the past year.
Price Volatility
| ASRT volatility | |
|---|---|
| ASRT Average Weekly Movement | 8.8% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ASRT has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ASRT's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 53 | Mark L. Reisenauer | www.assertiotx.com |
Assertio Holdings, Inc., a pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia.
Assertio Holdings, Inc. Fundamentals Summary
| ASRT fundamental statistics | |
|---|---|
| Market cap | US$119.23m |
| Earnings (TTM) | -US$30.37m |
| Revenue (TTM) | US$118.71m |
Is ASRT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ASRT income statement (TTM) | |
|---|---|
| Revenue | US$118.71m |
| Cost of Revenue | US$35.38m |
| Gross Profit | US$83.33m |
| Other Expenses | US$113.71m |
| Earnings | -US$30.37m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.71 |
| Gross Margin | 70.19% |
| Net Profit Margin | -25.59% |
| Debt/Equity Ratio | 41.6% |
How did ASRT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/03 01:08 |
| End of Day Share Price | 2026/05/01 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Assertio Holdings, Inc. is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| null null | Argus Research Company |
| Kenneth Trbovich | Brean Capital Historical (Janney Montgomery) |